Novo Nordisk A/S (NVO)’s Hemophilia Treatment "Blockbuster" Could be a Total Bust
8/13/2012 7:04:50 AM
Denmark's Novo Nordisk could be a few months away from dropping a drug expected to replace crucial blood treatment Novoseven and seen as a potential blockbuster, the company said on Friday. The world's biggest insulin producer said it could be forced to drop haemophilia drug candidate, vatreptacoq alfa, unless phase III data proved very favorable. Drugs are classed as blockbusters if they reach annual sales above $1 billion within five years of launch. "Unless we get really good clinical results, and we will know in October if we do, we will have to drop the studies," Novo's Chief Scientific Officer Mads Krogsgaard told Reuters in an interview.